Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1020 | Interdisciplinary Endocrinology 2 | ECE2019

Circulating miRNAs expression profile in in vitro muscle cell model exposed to cortisol excess

Patalano Roberta , Pivonello Claudia , Monto Tatiana , Simeoli Chiara , Negri Mariarosaria , Di Gennaro Gilda , Papa Fortuna , de Angelis Cristina , Cristina De Martino Maria , Pivonello Rosario

CushingÂ’s Syndrome (CS) is associated with a severe myopathy mainly affecting type 2 muscle fibres, with a higher prevalence in male subjects. The excess of glucocorticoids (GC) levels represents the most common cause of myopathy due to an alteration of protein metabolism. The non-coding post-transcriptional gene regulators muscle-specific microRNAs (miRNA) control muscle development and differentiation but when dysregulated lead to skeletal muscle (SM) disorder. The aim ...

ea0049ep34 | Adrenal cortex (to include Cushing's) | ECE2017

The treatment with dual release hydrocortisone in patients with adrenal insufficiency: correlation between change of the evening cortisol exposure time profile and change in metabolic profile, depression status and quality of life

Simeoli Chiara , Ferrigno Rosario , Pivonello Claudia , Auriemma Renata Simona , Negri Mariarosaria , Di Gennaro Gilda , Iacuaniello Davide , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (CGCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), resulting in increased metabolic morbidity and impaired quality of life (QoL). Non-physiological cortisol pattern and elevated evening cortisol levels may be responsible for the increased risk of metabolic disorders observed in AI patients under CGCs. Once daily dual-release-hydrocortisone (DR-HC), which better reproduces physiological daily cortisol profile, si...

ea0041gp17 | Adrenal (1) | ECE2016

Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile

Simeoli Chiara , Ferrigno Rosario , De Martino Maria Cristina , Auriemma Renata Simona , Pivonello Claudia , Negri Mariarosaria , Iacuaniello Davide , Di Gennaro Gilda , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (GCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), with a significant impact on morbidity and mortality. Possible explanations are supra-physiological doses and impaired cortisol profile. In particular, elevated evening cortisol levels were related to glucose tolerance and insulin sensitivity alterations and visceral obesity. Once-daily-dual-release-hydrocortisone (OD-DR-HC), better reproducing the physiological ...

ea0041ep620 | Endocrine tumours and neoplasia | ECE2016

Potential role of the adrenolitic drug mitotane in the treatment of hepatocarcinoma (HCC): effect on cell proliferation in HCC cell lines

Pivonello Claudia , Provvisiero Donatella Paola , Negri Mariarosaria , Di Gennaro Gilda , De Angelis Cristina , Simeoli Chiara , Patalano Roberta , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

HCC is one of the most common malignancies worldwide. Local approaches are generally preferred for patients whose disease is restricted to the liver. In patients with extrahepatic disease systemic therapy can be considered. Chemotherapy did not demonstrate convincing survival advantages in several trails for HCC patients. Presently, the kinase inhibitor sorafenib is the only approved systemic target therapy for the treatment of advanced HCC. Mitotane (dichlorodiphenildichloroe...

ea0041ep628 | Endocrine tumours and neoplasia | ECE2016

Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1,25(OH)vitamin D (VITD) reverts everolimus (EVE) resistance in a HCC cell line

Pivonello Claudia , Provvisiero Donatella Paola , Negri Mariarosaria , Di Gennaro Gilda , De Angelis Cristina , Galdiero Giacomo , Simeoli Chiara , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

HCC is a difficult-to-treat- cancer with poor prognosis. The recent EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib treatment. In selected patients, the well-established antitumor effect of EVE could make this drug a potential adjuvant therapy. Unfortunately, the acquired resistance to this molecule due to the tumor adaptation to chronic drug use is a current challe...

ea0056gp34 | Adrenal cortex | ECE2018

Effects of replication of the physiological and non-physiological cortisol rhythm on insulin sensitivity in muscle: a molecular in vitro analysis on synchronized muscular cells

Negri Mariarosaria , Di Gennaro Gilda , Pivonello Claudia , Simeoli Chiara , Vennery Mary Anna , Barbagallo Federica , Iacuaniello Davide , De Martino Maria Cristina , Isidoro Andrea Maria , Colao Annamaria , Pivonello Rosario

Adrenal insufficiency is a rare endocrine disorder characterized by low levels of cortisol associated with increased mortality, also due to inadequate replacement therapy. The replacement with the thrice-daily immediate release hydrocortisone (IRH), in contrast to the once-daily modified-release hydrocortisone (MRH), more appropriately mimicking the physiological circadian rhythm of cortisol (PCRC), is associated with metabolic disorders, mainly due to the non-physiological pe...

ea0056p674 | Nuclear receptors and Signal transduction | ECE2018

1,25 dihydroxyvitamin D reverses everolimus resistance in hepatocellular carcinoma activating mesenchymal-epithelial transition and miR-375

Pivonello Claudia , Paola Provvisiero Donatella , Negri Mariarosaria , Di Gennaro Gilda , de Angelis Cristina , Patalano Roberta , Galdiero Giacomo , Simeoli Chiara , Simona Auriemma Renata , Cristina De Martino Maria , Colao Annamaria , Pivonello Rosario

HCC is a difficult-to-treat-cancer with poor prognosis. EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib. In selected patients, the well-established antitumor effect of EVE could make this a potential adjuvant therapy. Unfortunately, EVE acquired resistance due to the tumor adaptation to chronic drug use is a current challenge. VitD was deemed as potential regimen to...